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Abstract
Background: Expression of inflammatory cytokines in cerebrospinal fluid (CSF) has led to the hypothesis of
intrathecal chronic inflammation to explain the denervation observed in post-polio syndrome (PPS). It has been
shown that therapy with intravenous immunoglobulin (IVIG) improves physical performance and dampens down
the inflammatory process at 6 months in PPS patients. We here examined the effects of IVIG on cytokine expression
and clinical outcome one year after IVIG treatment.
Methods: From a previous study with 135 PPS patients included, 41 patients were further evaluated before un-
blinding for one year (21 placebo and 20 treated with IVIG, XepolW 50 mg/ml), and were assessed for clinical
variables by performing the Short Form-36 survey (SF-36) questionnaire assessment, the 6 minute walk distance test
(6MWT) and registering pain level by Visual Analogue Scale (VAS) after IVIG treatment. A separate cohort of 37 PPS
patients went through lumbar puncture (LP) at baseline and 20 patients, treated with IVIG, repeated the LP one
year later. Thirty patients affected with other neurological diseases (OND) were used as control group. Inflammatory
cytokines TNF, TGFβ, IFNγ, IL-23, IL-13 and IL-10 were measured in blood cells and CSF cells with RT-PCR.
Results: Scores of the physical components of SF-36 were significantly higher at the one year follow up time-point
in the IVIG-treated patients when compared to baseline as well as to the control subjects. Pain VAS score and
6MWT improved significantly in the IVIG-treated patients when compared with baseline Relative expression of TNF
and IFN-γ in both PBMCs and CSF from PPS patients were increased compared to OND subjects at baseline
(p< 0.05). One year after IVIG-treatment a decreased expression of IFN-γ and IL23 was found in CSF of PPS patients,
while anti-inflammatory IL-13 was increased (p< 0.05).
Conclusions: IVIG has effects on relevant QoL variables and inflammatory cytokines up to one year in patients with
PPS. This gives a basis for scheduling IVIG in upcoming trials with this therapy.
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Background
The post-polio syndrome (PPS) may appear several dec-
ades after an acute poliomyelitis. The late symptoms
characterizing PPS are increased or new muscle weak-
ness, fatigue and pain leading to gait disturbances,
breathing difficulties as well as swallowing problems
[1-3]. It is estimated that 15-85% of poliomyelitis survi-
vors develop PPS (depending on criteria and population)
[1]. As the number of survivors is large, approximately
20,000,000 people world-wide, PPS is one of most com-
mon motor neuron diseases [3]. Current diagnosis is
based on thorough clinical examinations in order to
eliminate other possible diagnosis. Once a diagnosis has
been made, treatment options can be considered, which
so far mainly has been various forms of rehabilitation
and physiotherapy.
In PPS, there is an ongoing denervation which may ex-
plain the increased weakness in muscles earlier affected
by poliomyelitis [4,5]. The denervation is compensated
by collateral sprouting leading to an increase of the area
of the motor units. However, reinnervation cannot suffi-
ciently compensate for denervation leading to whole or
partial loss of motor units followed by a decrease of
muscle strength [4]. It is debated whether this deterior-
ation is caused by further loss of motor neurons due
to normal aging, genetics, deleterious over-use of
remaining motor neurons, and/or an active disease
process, perhaps involving chronic intrathecal inflamma-
tory damage [6-10]. These observations are supported by
our and others’ findings of and increased expression of
pro-inflammatory cytokines particularly in the intra-
thecal compartment [11-15]. The driving force of this in-
flammation has remained unclear. However, if the
deterioration is indeed driven by inflammation, it should
be accessible for therapy.
In a series of studies we have explored if intravenous
immunoglobulin (IVIG) treatment can affect the clinical
condition and signs of inflammation. This treatment
modality was chosen because of the pattern of the in-
flammatory process and since it has been reported to be
beneficial in other neuro-inflammatory conditions with a
good safety profile. A dampening down of the pro-
inflammatory cytokines was found when IVIG was admi-
nistered [13] and assessment of clinical variables in this
cohort showed beneficial effects [16]. We then per-
formed a double blind placebo controlled study with
clinical endpoints evaluated 6 months after treatment.
The study revealed significant effects on muscular
strength, physical activity, and quality of life (QoL)
regarding vitality and pain at six months after treatment
[17]. A smaller placebo controlled study and a recently
performed open study have documented significant
effects on pain [14,18]. However, the analysis of cytokine
expression profile has been limited to few patients and
restricted sets of cytokines, limiting the options of any
correlations to clinical disease variables.
Widespread recommendation for IVIG use in PPS
would require replication in independent studies, which
would need to consider dosing intervals. While most
chronic neuro-inflammatory diseases other than PPS re-
quire several courses of IVIG each year, at relatively high
cost, our clinical impression is that IVIG in PPS cause
improvements over longer periods, and that quite infre-
quent dosing would be necessary. Thus, on the basis that
pro-inflammatory cytokines are dampened down 2–
3 months [15], and knowing that effects on clinical vari-
ables are present 6 months after treatment [17], we now
evaluated the IVIG treatment effects on these measures
one year after treatment in an extended set of patients.
Such data would give a basis for choosing intervals of
repeated dosing of the drug.
Methods
Study design
A clinical study extension from the previous double
blind placebo controlled trial in which 135 PPS patients
were evaluated for clinical endpoints 6 months after
treatment [17], was performed. A cohort of 41 patients
from one of the 4 participating centers in the previous
study (the Danderyd Hospital), were recruited and fur-
ther evaluated, before un-blinding, one year later. They
were asked to perform the SF-36 Questionnaire, the 6
minute walk distance test and pain status evaluation
according to the Visual analogue scale (VAS). After
breaking of the trial code (un-blinding) it turned out
that this group consisted of 20 IVIG treated patients
(mean age 61.7 years, range 52–75, 70% females) and 21
from the placebo group (mean age 61.9 years. range 46–
75. 57.1% females). Lumbar puncture (LP) was not
included in the protocol of the original study. Thus, this
study was complemented with a cytokine expression
analysis including 37 patients from the placebo-treated
group of the previous trial [17], 17 of them dropped out
and 20 completed the study one year later. Thirty
patients affected with other neurological diseases (OND)
(mean age 41.4 years, range 24–61, 70% females) going
through neurologic diagnostic work up were used as
control group. The diagnosis of the OND group were as
follow: Ependymoma (n = 1), Dissociative syndrome
(n = 3), Cerebral infarction (late effect) (n = 1), Migraine
(n = 1), Neurastenia (n = 1), Neuromuscular bladder dis-
turbance (n = 2), Psychosis (n = 5), Sensory symptoms
(n = 3), Spinal stenosis (n = 2), Tension headache (n = 3),
Vertebral dissection (n = 1), Vertigo (n = 3), Paresthesia
(n = 4). Cytokine expression was evaluated through rela-
tive quantization of mRNAs by real-time quantitative
RT-PCR. Selected cytokines for analysis were: pro-
inflammatory, Th1 pathway-related such as tumor
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necrosis factor (TNF) and interferon-γ (IFN-γ); Th17
pathway-related such as IL-23; and anti-inflammatory,
Th2 pathway-related such as IL-10 IL-13, and TGF-β.
Flow of patients and data available for analysis are
shown in Figure 1.
Study subjects
For the clinical study extension, patients were diagnosed
and included according to previously reported criteria
[17,19]. Included patients had been randomized to either
intravenous infusion of IVIG (Xepol™ human immuno-
globulin 50 mg/ml solution for intravenous infusion,
batch number IAGD1HDHC1, Instituto Grifols S.A.,
Barcelona, Spain) or placebo consisting of solution in
bottles of identical size and appearance (Instituto Grifols
S.A., Barcelona, Spain). A total of 90 g of IVIG was given
and repeated 3 months later. The placebo solution con-
tained glucose and water for injection. The dosage levels
and infusion periods are described elsewhere [17].
For the cytokine expression study, PPS patients were
subjected to venous and lumbar puncture before the ad-
ministration of a single dose of IVIG (90 g) to perform
the analysis of cytokines in peripheral blood mono-
nuclear cells (PBMCs) and the CSF. One year after IVIG
infusion, 20 patients out of the 37 recruited volunteered
for another blood test and lumbar puncture. Blood and
CSF samples of patients with OND (n= 30) were
obtained from the in-house biobank at Karolinska Uni-
versity Hospital containing samples collected during
routine neurological diagnostic work-up. All enrolments
to the study followed the recommendations of the dec-
laration of Helsinki and the study was approved by the
Ethics committee of the Karolinska Institutet. Oral and
written information was given to the patients and con-
firmed consent in writing was received before inclusion.
Short form-36 survey
The Short Form-36 survey (SF-36) is a widely used and
extensively validated QoL instrument that contains 36
items that assess patients’ health status and its impact
on their lives [20,21]. The SF-36 is composed of eight
multi-item scales (Physical Functioning, Role-Physical,
Bodily Pain, General Health, Vitality, Social Functioning,
Role-Emotional, Mental Health), with scores ranging
from 0 to 100. Higher scores indicate higher QoL.
Data from the instrument can also be used to calculate
two summary scores, the Physical Component Summary
(PCS) and the Mental Component Summary (MCS).
These summary scales are computed as standardized
scores such that a mean score of 50 corresponds to that
of the general US population. For the PCS and MCS
scales, a change of 5.0 points was considered a clinically
meaningful difference.
The psychometric performance of the SF-36 has been
well established across a wide variety of disease states
[22-26]. The language versions used in the studies were
obtained from the developer and were administered as
patient-completed paper-and-pencil instruments with no
allowance for proxy completion.
Walking ability assessment
Walking ability was measured by the 6-minute walk test
(6MWT) [27,28]. The subjects were asked to walk a
measured distance (25 meters) back and forth at an indi-
vidually chosen speed for 6 minutes. Assistive devices
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Figure 1 Flow of patients through the study and data available for analysis
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situation for the patient and, if so, were registered so the
second test could be performed under the same condi-
tions. A longer distance is suggestive of increased walk-
ing ability.
Pain assessment
The Visual Analogue Scale (VAS) [29] was used to
evaluate the pain level. It consists of a 100-mm scale
where 100 mm stands for the worst imaginable pain and
zero stands for no pain.
Blood and CSF sampling
Paired CSF and blood samples were available. Peripheral
blood (PB) was sampled in sodium citrate-containing
cell preparation tubes (Vacutainer CPT, Becton Dickin-
son and Company, USA) and CSF in siliconized glass
tubes or polypropylene tubes. CSF samples were imme-
diately centrifuged and the pellet was recovered and
stored at −80 °C. PBMCs were separated by density gra-
dient centrifugation. Cells from the interphase were col-
lected and washed twice with Dulbecco´s PBS. The
proportion of viable cells was assessed by trypan blue
exclusion. Finally, the cells were pelleted, frozen on dry
ice and stored at −80 °C until use.
Relative quantitation of mRNAs by real-time quantitative
RT-PCR
Cell pellets were lysed and total RNA was extracted
(PicoPure RNA isolation kit, Arcturus Bioscience Mt.
View, CA). Samples were incubated with DNAase (Qia-
gen RNAase free DNAase set, Hilden, Germany) for
15 min. at RT in order to avoid amplification/detection
of contaminating genomic DNA. Reverse transcription
was performed with 10 μl total RNA (5–10 ng), random
hexamer primers (0.1 μg; Gibco BRL) and Superscript
Reverse Transcriptase (200 U; Gibco BRL). Real-time
PCR was performed using a BioRad iQ5 iCycler Detec-
tion System (BioRad Laboratories, Ltd) with a three-step
PCR protocol (95 °C for 10 min. followed by 50 cycles of
95 °C for 15 sec., 60 °C for 30 sec. and 72 °C for 30 sec.),
and with SYBR green fluorophore. Reactions were per-
formed in a total volume of 15μL including 7.5μL 2x
SYBR Green PCR Master Mix (BioRad Laboratories,
Ltd), 1.0μL of each primer at 5 μM concentration, 2μL
of the previously reverse-transcribed cDNA template
and 4.5μL double-destilated milli-Q H2O. Primers were
designed with the Primer Express Software (Perkin
Elmer) in our laboratory. The primer sequences for TNF
(Genbank Accession no: NM_000594) are: forward pri-
mer, 5´ CCA GGG ACC TCT CTC TAA TCA GC 3´;
reverse primer, 5´ CTC AGC TTG AGG GTT TGC
TAC A 3´. The primer sequences for IFN-γ (Genbank
Accession no: NM_000619) are: forward primer, 5´ GGT
TCT CTT GGC TGT TAC TG 3´; reverse primer, 5´
TCT GTC ACT CTC CTC TTT CC 3´. The primer
sequences for IL-23 (Genbank Accession no:
NM_016584) are: forward primer, 5´ CAA GTG GAA
GTG GGC AGA G 3´; reverse primer, 5´ CAG CAA
CAG CAG CAT TAC AG 3´. The primer sequences for
IL-10 (Genbank Accession no: NM_000572) are: forward
primer, 5´ GCT GGA GGA CTT TAA GGG TTA C 3´;
reverse primer, 5´ TTG ATG TCT GGG TCT TGG TTC
3´. The primer sequences for IL-13 (Genbank Accession
no: NM_002188) are: forward primer, 5´ ATT GCT CTC
ACT TGC CTT GG 3´; reverse primer, 5´ CTG GTT
CTG GGT GAT GTT G 3´. The primer sequences for
TGF-β (Genbank Accession no: NM_003239) are: for-
ward primer, 5´ AAC GAA CTG GCT GTC TGC 3´; re-
verse primer, 5´ CCT CTG CTC ATT CCG CTT AG 3´.
The primer sequences for GAPDH (Genbank Accession
no: NM_002046) are: forward primer, 5´AGG GCT GCT
TTT AAC TCT GGT AAA3´; reverse primer, 5´CAT
ATT GGA ACA TGT AAA CCA TGT AGT TG3´. The
primer pairs were tested by temperature gradient (55 °C
−65 °C for annealing step) programmed and the PCR
products were controlled by an agarose gel to for single
band of the expected size of each specific target. Sequen-
cing of the different bands (Cybergene AB, Huddinge,
Sweden) confirmed homology with the reported
sequences for human VAV1, TNFα and GAPDH respect-
ively. Relative quantitation of mRNA levels was performed
using the standard curve method, with amplification of
mRNA and GAPDH. The standard curves were created
using five serial dilutions (1:10, 1:102, 1:103, 1:104 and
1:105) of cDNA from human blood cells stimulated with
lectin (Con A). The samples were run in duplicate with
primers against GAPDH and the target mRNA in different
wells. Samples without added cDNA served as negative
controls. The relative amount of mRNA in each sample
was calculated as the ratio between the target mRNA and
the corresponding endogenous control GAPDH. The rela-
tive expression for each target was then normalized to an
arbitrary maximum value of 1.0 represented by the sample
with highest expression.
Statistics
Differences between groups and within groups regard-
ing clinical parameters were analyzed for significance
with the Mann–Whitney test and with the non-
parametric Wilcoxon´s signed-ranks test (JMP 3.2,
SAS Institute Inc., NC), respectively, since data were
not supposed to be equally distributed. Differences in
relative cytokine mRNA levels for comparing of OND
vs PPS were tested for significance with the Mann–
Whitney test, and for baseline vs IVIG-follow-up were
tested for significance with non-parametric Wilcoxon´s
matched-pairs signed-ranks test (JMP 3.2, SAS Insti-
tute Inc., NC). Correlations between clinical data and
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cytokine mRNA levels were analyzed with Spearman´s
rank (Sr) test. Analyses were done using the software
GraphPad Prism 5.0 (San Diego, CA, USA).
Results
Clinical study results
In the 41 patients cohort (20 IVIG-treated and 21
placebo-treated) that was followed in their clinical
parameters, the score of the QoL parameter SF-36
Physical Component Summary (PCS) reached statis-
tical significance (p = 0.020) at the one year follow up
time-point in favor of the IVIG treated patients and
also with respect to the baseline score before treat-
ment (p = 0.021). Similarly, even the sub domain
Physical Functioning (PF) was significantly different
between the groups (p = 0.028) and with respect to
baseline (p = 0.014). These results are summarized in
Table 1.
Pain score (VAS) decreased significantly at the one
year follow up in the IVIG treated patients (p = 0.013)
when compared with baseline. No change in VAS was
seen in the placebo group and there was no significant
difference between the IVIG and the placebo treated
patients at the one year follow up (Table 1).
Walking ability after one year showed a significant im-
provement in the IVIG treated patients (p< 0.001) but
not in the controls. There was no statistical difference
after one year follow up between the IVIG and placebo
group (Table 1).
Cytokine analysis results
Of the 37 patients with PPS that were recruited for
initial lumbar puncture and subsequent IVIG infusion,
mean age was 58.9 years (range 36–76 years), with a
56.8% of females, and 2 out of the 37 patients with oligo-
clonal bands in CSF. Of the 20 patients that volunteered
for the one-year follow up of cytokine analysis, mean age
was 62.7 years (range 49–79) with a,75.0% of females. In
the 30 subjects of the OND cohort, mean age was
41.4 years (range 24–61 years), with a 70.0% of females,
all of them without oligoclonal bands in CSF.
Values of cytokine mRNA expressions in the CSF cells
and PBMCs are shown in Table 2. At baseline levels
there was a significant increase of mRNA expression for
the two pro-inflammatory cytokines TNF and IFN-γ in
both CSF (Figure 2A and B) and blood (Figure 3A and
B) from PPS treated patients compared to the OND
group (TNF: CSF, p = 0.0358; PB p = 0.0164 and IFN- γ :
CSF, p = 0.0200; PB p = 0.0358), while none of the other
cytokines differed significantly between the groups
(Figure 2C–F and Figure 3C–F). For these cytokines
the CSF and blood levels correlated strongly (CSF:
Sr = 0.7472, p< 0.0001; PB: Sr = 0.5718, p< 0.0001)
(Figure 4A and B).
However, the TNF and IFN- γ levels did not correlate
in the same compartment (data not shown). Instead
there were many individuals with high TNF but low
IFN- γ in the same compartment. This prompted us to
add the levels of both cytokines together to visualize a
Table 1 Clinical parameters analysis (quality of life, QoL) according to the Short Form-36 (SF-36) survey and 6 minute
walk test (6MWT), comparing the IVIG-treated and placebo group
IVIG (n=20) Placebo (n=21) Between
SF-36
score
Before 1 year p Before 1 year p group
diff. pmean (SD) mean (SD) mean (SD) mean (SD)
PF 33.2 (17.9) 39.8 (19.2) 0.014 40.7 (22.7) 41.0 (22.0) 0.761 0.028
RP 30.0 (28.8) 42.5 (39.8) 0.240 50.0 (40.3) 48.0 (40.0) 0.757 0.278
BP 50.8 (18.1) 55.5 (21.6) 0.189 55.4 (24.5) 50.7 (27.3) 0.224 0.075
GH 53.1 (22.4) 61.3 (24.2) 0.058 58.1 (22.5) 61.8 (24.2) 0.190 0.290
VT 43.0 (22.6) 49.3 (27.3) 0.267 46.4 (23.8) 47.3 (22.2) 0.948 0.300
SF 66.9 (24.1) 73.8 (26.6) 0.094 70.8 (26.3) 71.4 (23.8) 0.897 0.191
RE 61.7 (43.6) 66.7 (40.5) 0.665 63.5 (43.3) 73.0 (38.9) 0.261 0.736
MH 74.4 (17.9) 76.0 (19.3) 0.652 72.6 (17.2) 72.5 (17.6) 0.881 0.844
PCS 28.9 (6.1) 32.8 (8.2) 0.021 34.0 (10.0) 33.1 (11.3) 0.394 0.020
MCS 48.7 (13.2) 50.0 (12.5) 0.681 47.6 (12.4) 49.3 (11.9) 0.192 0.531
VAS 31(24) 23(20) 0.013 31(22) 29(28) 0.509 0.449
6MWT, m 351 (110) 400 (112) <0.001 306 (111) 325 (125) 0.145 0.415
n=19 n=19 n=20 n=20
SF-36 scores range from 0 to 100. 6MWT are recorded in meters.
Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE) and Mental
Health (MH).
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Figure 2 Baseline levels of inflammatory cytokines in the cerebrospinal fluid (CSF) cells. Cytokines were measured in patients with Post-
polio syndrome (PPS) and with other neurological diseases (OND). The median-based box plots indicate 25th/75th percentiles and whiskers
indicate 5th/95th percentiles. Values of statistical significance are indicted (n.s.: non significant)
Table 2 Levels of cytokine relative expression in the cerebrospinal fluid (CSF) cells and peripheral blood mononuclear




CSF cells PBMCs CSF cells PBMCs
TNF* 0.204 ±0.0340 0.058 ±0.0071 0.112 ±0.0198 0.034 ±0.0060
IFN-γ* 0.281 ±0.0380 0.063 ±0.0072 0.158 ±0.0292 0.040 ±0.0082
TGF-β 0.391 ±0.0234 0.477 ±0.0275 0.398 ±0.0428 0.403 ±0.0440
IL-10 0.148 ±0.0283 0.009 ±0.0019 0.129 ±0.0367 0.011 ±0.0030
IL-13 0.336 ±0.0307 0.117 ±0.0087 0.426 ±0.0448 0.123 ±0.0092
IL-23 0.238 ±0.0446 0.103 ±0.0177 0.274 ±0.0333 0.125 ±0.0213
Values are expressed as mean ± SEM. * p<0.05 between patient groups and between compartments.
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combined form of pro-inflammatory cytokine levels.
With this procedure, the discrimination between PPS
and OND became more apparent and significant (CSF:
p = 0.0010; PB: p = 0.0023) (Figure 5A and B).
The effect of a single IVIG infusion was a significant
decrease of IFN- γ and IL- 23 mRNA expressions in
CSF cells (p = 0.0061 and p = 0.0465 respectively) after
one-year follow up in patients with PPS (Figure 6B and
C). There was a trend towards a sustained decrease for
TNF and a significant increase for IL-10 (Figure 6A and
D). IL-13 was also significantly increased (p = 0.0072)
(Figure 6E). TGF-β did not show any trend after one
year follow up (Figure 6F).
In peripheral blood no significant differences in
mRNA expressions of cytokines were detected in the
follow-up results (Figure 7A–F).
Discussion
PPS is a relatively slow but a consistently progressive
condition [1]. Due to these disease characteristics it is
difficult to detect changes in the condition following an
intervention in the short-term perspective. Our clinical
impression is that following an IVIG treatment the con-
dition has a peak improvement somewhere between
6 months and one year after a single infusion. The
























































































































Figure 3 Baseline levels of inflammatory cytokines in the peripheral blood mononuclear cells (PBMCs). Cytokines were measured in
patients with post-polio syndrome (PPS) and with other neurological diseases (OND). The median-based box plots indicate 25th/75th percentiles
and whiskers indicate 5th/95th percentiles. Values of statistical significance are indicted (n.s.: non significant)
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Although we did not have the opportunity to follow all
the patients in the previous larger study, we had a
chance to commit an evaluation of a subgroup of the
larger group. As a consequence, there are several limita-
tions of this study. First, the clinical study was per-
formed in a sub-group analysis from one center of the
initial trial and so it was not intentionally powered for
the analysis presented here. Second, the clinical and
cytokine parameters were not evaluated in the same co-
hort of patients since lumbar puncture was not a part of
the protocol of the original study. Thus, the results do
not allow for a direct correlation between clinical im-
provement and in the changes in the CSF cytokine pro-
file within the same cohorts. Nevertheless, since the
PPS population was homogeneous because it came from
the same previous clinical trial and the objective was to
observe IVIG effects after one year follow-up, the results
can still be validly discussed.
The clinical parameters at the one-year follow up
time-point showed that the physical component of SF-
36 was significantly increased in favor of the IVIG trea-
ted group. Interestingly, the physical component score
(PCS), which was one of the primary variables in the
Randomized Controlled Trial, was significantly higher in
the IVIG treated group at the one year follow up [17].
Moreover, the vitality sub domain of SF-36, on the con-
trary to the finding at 6 month [17], did not significantly
change between groups after one year follow up. How-
ever, pain assessment and walking ability parameters
positively evolved from before to after treatment in the
IVIG group.
We assume that infusion of IVIG causes a significant
increase in QoL for parameters related to physical func-
tion. In our opinion, the decreased and surprisingly long
lasting effect of a single dose of IVIG has an immediate








































Figure 5 Combined levels of pro-inflammatory cytokines in the
cerebrospinal fluid (CSF) cells and peripheral blood
mononuclear cells (PBMCs). Tumor necrosis factor (TNF) and
interferon γ (IFN-γ) were measured in patients with post-polio
syndrome (PPS) and with other neurological diseases (OND). The
median-based box plots indicate 25th/75th percentiles and whiskers
indicate 5th/95th percentiles. Values of statistical significance are
indicted (n.s.: non significant)





























Figure 4 Correlation study of pro-inflammatory cytokines in
systemic and intrathecal compartments.
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effect on vitality and pain. One may speculate that the
delayed effect on physical parameters could be the result
of an enhanced accommodation to routine activity level
as well as training and exercise. While in the previous
trial [17] the effect on pain could not be excluded as the
cause of the positive outcome on motor function, in the
present study no significant effect on pain was found in
this long term interval. In a recently published study a
favorable and statistically significant effect on pain was
found in PPS patients 6 months after IVIG treatment
[18]. Thus, there is a reason to believe that pain reduc-
tion may play a role in the improvement of quality of life
for physical function. Further investigation to shed light
on these questions is deserved.
To assess the role of inflammation in the same clin-
ical context, in this study we analyzed the cytokine
expression profile and immunological variables in
blood and CSF in a cohort of PPS patients, one year
after IVIG treatment. Consistent with our previous
findings [13], but in this report with a new technique
and with a larger number of cytokines, we confirm
that PPS patients have an active neuro-inflammatory
process with increase of Th1 cytokines both in the
CSF and to a smaller extent in the PB. Levels of pro-
tective cytokines such as IL-10 and IL-13 were similar
to those of control patients (OND) before treatment. It
is of importance to mention that to exploring the nor-
mal subjects with lumbar puncture is not an easy task.
For this reason, we have used a non-inflammatory
OND cohort as an alternative to healthy subjects
against neuroinflammatory conditions such as PPS in
this study. The OND cohort used for comparison of





















































































































Figure 6 Effects of intravenous immunoglobulin (IVIG) on levels of inflammatory cytokines in cerebrospinal fluid (CSF) cells. The
median-based box plots indicate 25th/75th percentiles and whiskers indicate 5th/95th percentiles. Values of statistical significance are indicted
(n.s.: non significant)
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baseline cytokine expression to PPS was rather hetero-
geneous, though care was taken to include persons
with non-inflammatory neurological disease. In
addition, this type of control subjects have in several
previous publications from our group displayed a low
expression of cytokines in blood and CSF compared to
well accepted inflammatory diseases like multiple sclerosis
[30,31]. After treatment with IVIG the Th1 cytokine levels
were significantly decreased while the levels of IL-10 and
IL-13 were significantly increased. Levels of IL-23 were low
in CSF at baseline, and decreased even more one year
after a single dose of IVIG. It has been shown that IL-23
participates in the pathogenesis of autoimmune inflam-
mation by promoting the development of a pathogenic
CD4+ T-cell population that produces IL-6, IL-17 and
tumor-necrosis factor (TNF) [32]. As this cytokine
promotes auto-inflammatory disease, one year lasting
IVIG-induced suppression of IL-23 and IFN-γ levels is
of special interest not only for PPS but also for other
neurological diseases. However, the fact that changes
induced by IVIG occur in the PBMCs as well as the CSF
cells may reflect some type of systemic process that cannot
be ruled out. CSF is more difficult to obtain and, thus, this
finding also suggest that cytokine analysis in PB may be
valid for studies of systematic inflammation and potentially
for selecting PPS patients for IVIG treatment.
In a recent study Melin et al. (K Borg 2012 personal com-
munication) were able to show an increase of enzymes
involved in the prostaglandin pathway in blood vessels of
muscle of PPS patients. This may be a background for pain
Figure 7 Effects of intravenous immunoglobulin (IVIG) on levels of inflammatory cytokines in peripheral blood mononuclear cells
(PBMCs). The median-based box plots indicate 25th/75th percentiles and whiskers indicate 5th/95th percentiles. Values of statistical significance
are indicted (n.s.: non significant)
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in PPS and may indicate the presence of a systemic process.
Further studies are needed to elucidate the role of prosta-
glandin and the possible effect of IVIG.
Conclusions
We suggest, on the basis of the data from the present
study, that infusion of IVIG causes beneficial changes in
the CSF cytokine profiles in PPS patients and that this
action is paralleled by a significant increase in QoL for
parameters related to physical function that persist even
one year after treatment. Our observations of long term
sustained effects of IVIG on clinical parameters in PPS, lays
the ground for treatment replication studies, with infre-
quent dosing intervals, as compared to many other chronic
neuro-inflammatory conditions. If successful, there is an
option for a relatively cheap, safe and effective treatment
modality in this chronic condition which previously has
lacked any options for immuno-modifying strategies.
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